26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

      Read this article at

      ScienceOpenPublisher
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Early-phase trials with monoclonal antibodies targeting PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death 1 ligand 1) have demonstrated durable clinical responses in patients with non-small-cell lung cancer (NSCLC). However, current assays for the prognostic and/or predictive role of tumor PD-L1 expression are not standardized with respect to either quantity or distribution of expression.

          Related collections

          Author and article information

          Journal
          JAMA Oncology
          JAMA Oncol
          American Medical Association (AMA)
          2374-2437
          January 01 2016
          January 01 2016
          : 2
          : 1
          : 46
          Affiliations
          [1 ]Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut2Department of Pathology, Yale University School of Medicine, New Haven, Connecticut
          [2 ]Department of Biostatistics, Yale University School of Public Health, New Haven, Connecticut
          [3 ]Department of Pathology, Yale University School of Medicine, New Haven, Connecticut
          [4 ]Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio
          [5 ]Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut
          Article
          10.1001/jamaoncol.2015.3638
          0ae8fa29-740b-4cec-9c67-46c896b7c1f0
          © 2016
          History

          Comments

          Comment on this article